Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

Ursinus College has received a $4 million pledge that when realized will be among the largest gifts ever to the 156-year-old ...

Pneumococcal Vaccine market Forecast to Surge to US$ 14.43 Billion by 2032, Achieving a Remarkable 6.4% CAGR ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 ... slightly down on the same period of 2023. MSD (known as Merck & Co in the US and Canada), meanwhile, recorded $647 million ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...